Looking back: Top 5 most-read Houston sports tech stories of 2024

year in review

Fan engagement, big partnerships, and cohorts announced — these were the top sports tech news articles this year. Photo via Getty Images

Editor's note: As the year comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. Houston is a city primed for sports tech innovation — with its collection of major sports teams, vibrant population, and tech workforce. Here are five sports tech news stories that stood out to readers this year — be sure to click through to read the full story.

10 sports tech startups named to Houston-based hybrid accelerator

Introducing the 10 startups participating in the Spring 2024 cohort of the DivInc Sports Tech Accelerator, a hybrid program based in the Ion. Photo via DivInc.com

DivInc has named its latest sports tech-focused cohort of its hybrid accelerator that is housed out of the Ion.

The Sports Tech Accelerator has selected the 10 companies — with technology across human performance, fan experience, and more — for its 13th cohort to participate in the 12-week hybrid program this month and through July.

The program receives support from underdog venture team, Women In Sports Tech, The Collectiv, and HTX Sports Tech, with partners Bank of America, J.P. Morgan Chase & Co., Gunderson Dettmer, Brown Advisory, Ion, and Mercury. Continue reading.

High-tech virtual racing experience to rev up in Houston

Houston is getting 16 racing simulators, each equipped with full motion systems and immersive, 180-degree panoramic displays. Photo by Dylan McEwan

Come next year, some high-speed and high-tech race simulators will be added to one of Houston's growing districts.

Velocity - Sim Racing Lounge, described in press materials as Houston’s first premium simulation racing experience, is slated to open in early 2025 at 2110 Edwards St.Velocity will bring sim racing to Houston through 16 racing simulators, each equipped with full motion systems and immersive, 180-degree panoramic displays. The goal is provide customers with a truly authentic, virtual driving experience.

Customers will have the ability to virtually drive sports cars from iconic brands like Porsche and Lamborghini and race on world famous tracks, including the Circuit of the Americas, Laguna Seca, and the Silverstone Circuit. Classic roads, such as California’s Pacific Coast Highway, provide a more leisurely alternative to driving flat out. Continue reading.

Rice University announces partnership with Houston sports tech startup to enhance student athletics

Rice University's athletic programs will be supported by Houston startup BeOne Sports' technology. Photo courtesy of Rice University

Rice University — in an effort to enhance athletics and research-driven innovation — has formed a partnership with a startup founded by its alumni.

BeOne Sports, a sports performance technology company developed a platform for mobile motion-capture AI and advanced data analytics, will integrate its technology within Rice's sports medicine and rehabilitation programs.

“This partnership aligns perfectly with Rice University’s mission to harness innovation for the betterment of our community,” Rice President Reginald DesRoches says in a news release. “By integrating cutting-edge technology from BeOne Sports with our already world-class athletic and academic programs, we are providing our student athletes with the tools they need to excel both on the field and in life. This collaboration is a testament to Rice’s commitment to leading through innovation and offering unparalleled opportunities for our students.” Continue reading.

Diversity-focused sports tech accelerator opens applications to Houston innovators for the first time

Calling all sports tech startups founded by Black or Hispanic innovators. Photo via Getty Images

A global organization has announced it's opening applications to its equity-focused sports tech accelerator to Houston founders for the first time.

Thanks to a collaboration with Impact Hub and Black Ambition, the adidas Community Lab has expanded its footprint and is now accepting applicants from new markets, including Houston, Toronto, Los Angeles, Atlanta, and New York, for its 2024-2025 cohort.

The initiative, which has been running for three years, has a goal of supporting Black and Latino/a/e founders with mentorship, pitch training, event programming, and networking. The eight-month program also has $75,000 in grant funding to dole out to participants as well. Continue reading.

Houston sports tech startup aims to optimize unsold resale ticket market with new platform

Looking to score the best deal on your next game ticket? A new Houston-founded app promises to revolutionize the resale market. Photo via Getty Images

Online platforms have long simplified the process of buying, selling, and trading event tickets. But what happens when your tickets don’t sell or when you’re stuck with costly season tickets you can’t use? You might end up giving them away or leaving them unused, leading to a financial loss either way.

This is the challenge that Houstonian Jerin Varkey is willing to address with Offer Approved, a new platform that empowers sellers and buyers, guaranteeing that no seat goes unused.

The idea took root around two years ago when Varkey, a passionate sports fan and season ticket holder, faced a new challenge. After becoming a parent, he found himself unable to attend every game. Frustrated with traditional resale platforms, he quickly realized that high fees and limited time made it difficult to sell all his tickets, causing him to lose money each time. Continue reading.

From Your Site Articles
This week's roundup of Houston innovators includes Bryton Praslicka of FluxWorks, Sarah Hein of March Biosciences, Jerin Varkey of Offer Approved. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three founders across therapeutics, space, and sports tech.

Bryton Praslicka, CEO and founder of FluxWorks

FluxWorks, a hardtech startup, opened its new home-base in Conroe, Texas. Photo courtesy FluxWorks

FluxWorks, a hardtech startup, recently opened its new base of operations in Workhub Developments’ Conroe location.

Founded in College Station by CEO Bryton Praslicka, FluxWorks specializes in making contactless magnetic gears for use in extreme conditions. At 9,000 square feet, the new Conroe facility is a result of discussions with Governor Greg Abbott's office and the Greater Houston Partnership, who introduced the company’s leadership to the Conroe Economic Development Council, encouraging their move, Praslicka tells InnovationMap.

“The pieces of the puzzle were all there, and with the support of the local, state, and federal government, we were thrilled to move to Conroe,” Paslicka says. Read more.

Sarah Hein, co-founder and CEO of March Biosciences

Sarah Hein joins the Houston Innovators Podcast to discuss how the company will use its series A funding. Photo via march.bio

When cancer originates in a patient, their body fights as hard as it can against the disease, but sometimes, the cancer wins the battle. However, one Houston cell therapy startup is working on an artillery of therapeutics to help arm patients' bodies to win the war.

Founded in 2022, March Biosciences is a cell therapy company born in part out of the Texas Medical Center's Accelerator for Cancer Therapeutics, where Sarah Hein served as inaugural entrepreneur in residence. In that role, she met her co-founders Max Mamonkin and Malcolm Brenner.

Now, leading the startup as CEO, Hein tells the Houston Innovators Podcast that with March's lead product, MB-105, an autologous CD5 CAR T cell therapy, the name of the game is to zero in on advancing this particular treatment to its phase II trial next year.

"Targeted therapies are targeted. Our target is expressed on these T-cell cancers, and there are a couple other cancers, like Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia," Hein says on the show. "Unfortunately, I don't think there's ever going to be a magic bullet that is going to hit a huge swath of these cancers. We're going to continue to chip away at these cancers by creating really elegantly engineered therapies against these different kinds of tumors.

"March, in general, is committed to this idea that we're going to continue to work on difficult tumors and different targets with our uniquely engineered targeting strategy against these diseases. As we expand into the next year, you'll see us speak on this a little more on how we're going to continue to work on new diseases that havent been addressed previously," she continues. Read more.

Jerin Varkey, founder and CEO of Offer Approved

Looking to score the best deal on your next game ticket? A new Houston-founded app promises to revolutionize the resale market. Photo via LinkedIn

Online platforms have long simplified the process of buying, selling, and trading event tickets. But what happens when your tickets don’t sell or when you’re stuck with costly season tickets you can’t use? You might end up giving them away or leaving them unused, leading to a financial loss either way.

This is the challenge that Houstonian Jerin Varkey is willing to address with Offer Approved, a new platform that empowers sellers and buyers, guaranteeing that no seat goes unused.

The idea took root around two years ago when Varkey, a passionate sports fan and season ticket holder, faced a new challenge. After becoming a parent, he found himself unable to attend every game. Frustrated with traditional resale platforms, he quickly realized that high fees and limited time made it difficult to sell all his tickets, causing him to lose money each time.

"I knew there was someone out there willing to pay $50," he recalls. Read more.

Looking to score the best deal on your next game ticket? A new Houston-founded app promises to revolutionize the resale market. Photo via Getty Images

Houston sports tech startup aims to optimize unsold resale ticket market with new platform

game on

Online platforms have long simplified the process of buying, selling, and trading event tickets. But what happens when your tickets don’t sell or when you’re stuck with costly season tickets you can’t use? You might end up giving them away or leaving them unused, leading to a financial loss either way.

This is the challenge that Houstonian Jerin Varkey is willing to address with Offer Approved, a new platform that empowers sellers and buyers, guaranteeing that no seat goes unused.

The idea took root around two years ago when Varkey, a passionate sports fan and season ticket holder, faced a new challenge. After becoming a parent, he found himself unable to attend every game. Frustrated with traditional resale platforms, he quickly realized that high fees and limited time made it difficult to sell all his tickets, causing him to lose money each time.

"I knew there was someone out there willing to pay $50," he recalls.

A transparent market for resale tickets


Offer Approved is a transparent and trusted platform for both sellers and buyers. Screenshots courtesy of Offer Approved

With this idea in mind, he started intensive research through 2023, identifying the multiple inefficiencies in the ticket market, including seeing the same seat in different marketplaces simultaneously.

“You’ll go through the checkout process and discover that those seats are no longer available; what happens is somebody bought it a few seconds before you on a different site, and the new system is taking it down," Varkey tells InnovationMap.

Scams, falsification, and security flaws were also among the problems. Offer Approved aims to fix these gaps by offering a transparent and trusted platform for both sellers and buyers, specifically to season ticket holders who leave several seats empty at stadiums each night.

“Sellers now have better visibility into the market, and we assist them in managing their listings," Varkey explains. "If a ticket is listed at $100, the seller can set a hidden minimum price of $80 or $70. Any offer that meets or exceeds that amount is automatically accepted, saving them the hassle of manually adjusting prices each time.”

A business model focused on sustainable growth

Varkey initially partnered with angel investors to bring the developer and a technical team. He prefers to avoid paid advertising, opting instead for a more sustainable business approach, including a small fee for sellers and a service charge for managing season tickets.

The project is currently self-funded, and Varkey is focused on ensuring long-term sustainability.

"I'm perfectly fine with taking things slowly. My priority is to make sure the model is sound first," he says.

Offer Approved is currently seeking season ticket holders and partnerships to build supply. He has also been in conversations with Toyota Center, NRG Stadium, and Minute Maid Park and their sports teams.

From corporate worker to visionary founder

Jerin Varkey founded Offer Approved to target unsold resale tickets to sporting events. Photo courtesy of Offer Approved

Varkey’s entrepreneurial journey started in the corporate world at Shell where he worked for ten years within capital project management and business improvement.

“It was a great experience, and I learned a lot, but I constantly felt the urge to say, 'This could be improved if we made some changes.' That kind of flexibility just wasn't possible in large corporate environments,” he recalls.

Varkey says he always tried to build innovative projects on the side until he finally left the company in 2018 and started working for venture-backed startups, where he found a space to bring his ideas to life.

For the past five years, Varkey has worked for startups like Gympass and Entera as a head of strategy and analytics. Now, as the founder of Offer Approved, he continues to work on new projects while driving his ticketing platform forward in Houston.

Varkey’s vision goes beyond just sports tickets and local markets — he aims to expand into areas like restaurant reservations, hotel stays, and other time-sensitive services, even offering deals to clients when traveling or exploring new cities.

“I believe in the power of negotiation, and I envision a future where people can make offers on anything with an expiration date,” he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.

View All Listings